BioMed Realty has signed a trio of tenants at its soon-to-be-built laboratory space at Babraham Research Campus in Cambridgeshire.
Insmed, a Nasdaq-listed company focused on drug development for patients with serious and rare diseases, will occupy 17,000 sq ft, while biotech company Xap Therapeutics has leased 10,000 sq ft.
Both tenants will move from existing facilities within Babraham Research Campus to the more expansive scale-up labs in the new building.
Mosaic, an oncology therapeutics company, will take the remaining 6,800 sq ft. The start-up is an alumnus of the 2021/22 cycle of Accelerate@Babraham bio-incubator programme, which is backed by BioMed.
The 34,000 sq ft building is being delivered in a joint venture partnership with BRC, which is responsible for the development and management of the campus on behalf of its shareholders, BBSRC-UKRI and the Babraham Institute. It is due for completion in February.
The scheme features fitted lab and office suites designed for multi-tenant flexibility. It is set to be the most sustainable building on campus to date, targeting a BREEAM Excellent certification.
Bill Kane, president of East Coast and UK markets at BioMed, said: “By investing in the mission-critical facilities that will help nurture innovation, our joint venture with Babraham Research Campus will help provide the UK’s life sciences industry with a path for growth and allow the sector to continue competing globally.”
Derek Jones, chief executive at Babraham Research Campus, added: “Ongoing development of the campus is designed to continually enhance our ecosystem. This provides opportunities for ventures to start and scale with us, responding to requirements as they evolve with the right physical facilities, as well as access to our wider community, both on and off campus.”
Cheffins advised BioMed.
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
